JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today the online publication of abstracts for presentations by the company and its collaborators concerning the development of the company’s lead phase 3 products LX211 and LX201, as well as two earlier stage projects. The presentations will be part of the upcoming ARVO 2008 Annual Meeting, “Eyes on Innovation,” to be held April 27 – May 1, 2008 in Fort Lauderdale, FL. Access to the published abstracts is available on the ARVO website at http://www.arvo.org.
“We will be showcasing at ARVO the depth of Lux Biosciences’ development pipeline, and we are very pleased to report remarkable progress with all of our projects,” said Ulrich Grau, Ph.D., Lux Biosciences President and Chief Executive Officer. “Notably, during this meeting we have presentations on our two phase 3 clinical programs in uveitis and in cornea transplantation. We also will be presenting highly original work with bioerodible polymers as well as a clear, mixed micellar formulation for ocular delivery of our next generation calcineurin inhibitor (LX212 and LX214, respectively). These latter two product candidates are tailor-made for dry eye and other, highly prevalent chronic inflammatory diseases of the eye.”
About Lux Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused on ophthalmic diseases. The company has a staged product portfolio of potentially first-in-class therapies distinguished by their short-term path to commercialization and potential to generate high revenue growth. The portfolio includes:
Two Phase III clinical-stage projects including: i) LX211, the oral formulation of a next-generation calcineurin inhibitor developed as steroid sparing therapy for the treatment of non-infectious uveitis, and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye for the prevention of rejection cornea transplant recipients. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007 and include sites in North America and Europe. LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in mid 2008. LX214 is based on Lux’ proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis. Several earlier stage projects based on proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye. For more information on Lux Biosciences, please visit the company’s website at http://www.luxbio.com.
Contact: Lux Biosciences, Inc. Ulrich Grau, Ph.D., +1-201-946-0221 Ulrich.grau@luxbio.com or Kureczka/Martin Associates Joan Kureczka, +1-415-821-2413 (Media) Jkureczka@comcast.net
Source: Lux Biosciences, Inc.
